Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients

NCT05364671 is registered in ClinicalTrials.gov with Materia Medica Holding as lead sponsor.

NCT NCT05364671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05364671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients
Lead sponsor
Materia Medica Holding
Phase
Phase 3
Overall status
Completed
Start date
April 29, 2022
Completion date
August 18, 2023
Enrollment
771 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019 (covid-19)